Appln. No.:	09/ Series Code ↑	697,297 Serial No. 1	
Filed: Oct	ober 27, 2000		VILE A
	ssioner of Patents		
Washington,	D.C. 20231	į	NOV 2 1 2002
Sir:			Cin and
•	REPLY/AMENDA	/IENT/LET	ER TRADE

Group Art Unit 1632

Examiner: J. T. Woitach

Atty. Dkt. 0277165

Appln. Title: Gynogenetic or Androgenetic Produciton

of Pluripotent Cells and Cell Lines, And Use Thereof to Produce Differentiated

Client Ref

Cells and Tissues

Date: November 21, 2002

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim							
A. ☐ NOT made B. ☐ Withdrawn C. ☐ made herewith D. ☒ made previously A. ☐ NOT made See Required Separate Paper (Pat-256)	Claims Highest number remaining after amendment		Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm	
2. Total Effective Claims	57	**minus	38	19	x \$18/\$9 =	+ \$171	103/203
3. Independent Claims	5	***minus	4	1	x \$84/\$42 =	+ \$42	102/202
4. If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time (leave <u>blank</u> if this is a <u>reissue</u> application)						+ \$0	104/204
5. Original due Date: November 2		NONE	1 mo)	\$110/\$55 =			
6. Petition is hereby made to extend			115/215				
date to cover the date this response i	s filed for which		mos)	\$400/\$200 =	+ \$0		116/216 117/217
requisite fee is attached (3 mos) \$920/\$460 =							118/217
		•	mos) mos)	\$1,440/\$720= \$1,960/\$980=			128/228
7. Enter any previous extension fee g	- \$0						
8.					Extension Fee	+ \$0	
9. If Terminal Disclaimer attached, a	+ \$110/\$55	+ \$0	148/248				
10. If IDS attached requires Official F or if Rule 97(d) Request	+ \$180 + \$180	+ \$0	126 126				
11. After-Final Request Fee per rules 129(a) and 17(r) + \$740/3						+ \$0	146/246
12. No. of additional inventions for ex	x \$740/370 ea	+\$0	149/249				
13. Request for Continued Examination	+ \$740/370	+ \$0	1179/1279				
14. Petition fee for	+ \$0						
15.	\$213						
16. *If the entry in this space is less than entry 17. **If the "Highest number previously paid 18. ***If the "Highest number previously paid 18. ***If the "Highest number previously paid 19. ***If the "Hig	PLEASE CHARGE OUR DEP. ACCT						
CHARGE OTATEMENT. The Owner,			Our	Deposit Account r Order No015			

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Sig:

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP Intellectual Property Group Robin L. Teskin By Atty:

McLean, VA 22102 Tel: (703) 905-2000

Fax: Tel:

Reg. No.

(703) 905-2500 **(703) 905-2500**

Atty/Sec: RLT/af

P.O. Box 10500

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments NOV $\,2\,\,6\,\,2002$





ED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

James M. Robl et al.

Group Art Unit: 1632

Application Serial No. 09/697,297

Examiner: J.T.Woitach

Filed: October 27, 2000

Title: GYNOGENETIC OR ADROGENETIC PRODUCTION OF PLURIPOTENT CELLS AND CELL

LINES, AND USE THEREOF TO PRODUCE DIFFERENTIATED CELLS AND TISSUES

REPLY PURSUANT TO 37 C.F.R. §1.111

RECEIVED

NOV 2 6 2002

Hon. Commissioner of Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Office Action [Non-Final Rejection] dated August 28, 2002, please amend the above-identified application as follows. Changes made are indicated in the attached Appendix.

In the Specification:

Please delete the paragraph beginning at page 1, line 5, and replace it with the following rewritten paragraph:

-- Cross Reference to Related Application

This application claims priority from U.S. Provisional Application Serial No. 60/161,987 filed on October 18, 1999.

Please delete the paragraph beginning at page 1, line 10, and replace it with the following rewritten paragraph:

200E CHADELRA 00000119 033975